KIAA1549 and neoplasm: Subsequent clinical studies examining the use of a type I RAF inhibitors, such as sorafenib, in KIAA1549-BRAF–fused PAs were unfortunately met with paradoxical upregulation of the MAPK pathway and marked tumor growth (37).